Is AbbVie Inc. (ABBV) Undervalued?
The traditional Graham Number cannot be calculated for AbbVie Inc. (ABBV) due to missing data. Consider using DCF or other valuation methods for a complete picture.
Analysis updated March 6, 2026
ABBV Key Valuation Metrics
| Metric | Value | Signal |
|---|---|---|
| Current Price | $231.34 | — |
| Graham Number | N/A | — |
| P/E Ratio | N/A | Unprofitable |
| P/B Ratio | -125.95 | ▲ Low |
| DCF Fair Value | N/A | — |
| Dividend Yield | 2.87% | — Moderate |
| 52-Week Range | $164.39 – $244.81 | Near 52-week high |
| Market Cap | N/A | Micro Cap |
| Sector | Healthcare | — |
How We Calculated ABBV's Graham Number
The Graham Number, developed by Benjamin Graham (the father of value investing), estimates a stock's maximum fair price based on its earnings and book value.
Graham Number = √(22.5 × EPS × BVPS)
For AbbVie Inc. (ABBV):
- Earnings Per Share (EPS): N/A
- Book Value Per Share (BVPS): N/A
ABBV Dividend Profile
AbbVie Inc. currently pays a quarterly dividend of $1.66 per share, yielding 2.87% at the current price.
| Annual Dividend | $6.65 |
| Dividend Yield | 2.87% |
| Payout Ratio | N/A |
| Consecutive Years Paid | 5+ years |
| 5-Year Dividend Growth | -11.5% |
| Payment Frequency | Quarterly |
👑 AbbVie Inc. is a Dividend Aristocrat — it has increased its dividend for 25+ consecutive years.
Dividend History
ABBV Value Score: 2/10
Our proprietary value score rates AbbVie Inc. a 2 out of 10, placing it in the “Overvalued / Caution” category for value investors.
Score Components
Graham Number not available
P/E not available
Trading near or below book value
DCF value not available
Solid 2.9% yield
Weak balance sheet metrics
Score methodology: How We Score Stocks
Stocks Similar to ABBV
These Healthcare stocks have similar valuation profiles to AbbVie Inc.:
Frequently Asked Questions About ABBV
Is ABBV undervalued right now?
Based on Graham Number analysis, ABBV does not appear significantly undervalued as of March 6, 2026. The Graham Number of $N/A compared to the current price of $231.34 indicates a N/A% difference.
What is AbbVie Inc.'s intrinsic value?
Using our DCF model, AbbVie Inc.'s estimated intrinsic value is $N/A per share. The Graham Number suggests a fair value of $N/A.
What is the Graham Number for ABBV?
The Graham Number for ABBV is $N/A, calculated using EPS of $N/A and Book Value Per Share of $N/A. The formula is sqrt(22.5 x EPS x BVPS).
Does ABBV pay a dividend?
Yes, ABBV pays dividends with a yield of 2.87%. The annual dividend is $6.65 per share. It has paid dividends for 5+ consecutive years.
Is ABBV a good buy right now?
Our value score rates ABBV a 2/10. The stock is in the "Overvalued / Caution" category. However, this is analysis — not financial advice. Consider your own risk tolerance, portfolio allocation, and investment timeline before making any decisions.
Start Analyzing ABBV Today
Ready to invest in AbbVie Inc.? Open a free brokerage account and start trading ABBV with $0 commissions.
We may earn a commission when you open an account through our links. This does not affect our analysis or ratings.
Learn More About Value Investing
Tools
- Graham Number Calculator — Calculate the Graham Number for any stock
- DCF Calculator — Run your own discounted cash flow analysis
- Stock Screener — Filter stocks by value metrics
Related Articles
About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLE...
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial advice, a recommendation, or a solicitation to buy or sell any security. Past performance does not guarantee future results. Always do your own research and consult a licensed financial advisor before making investment decisions. Data sourced from Financial Modeling Prep API and may be delayed. Last updated: March 6, 2026.